NNVC -- NanoViricides, Inc. Announces First Quarter Updates
WEST HAVEN, Conn.--(BUSINESS WIRE)--April 18, 2006 -- NanoViricides, Inc. (PINK SHEETS:NNVC), a biopharmaceutical company specializing in unique antiviral treatments that utilize its patented nanomicelle(TM), today announced several first-quarter updates.
The entire scientific staff, led by NanoViricides, Inc. President Dr. Anil Diwan, is currently in Vietnam preparing experimental material for the previously announced H5N1/AviFluCide-I(TM) trials. They are also meeting with Health Ministry officials to discuss future anti-rabies trials.
"The initial portion of the H5N1/AviFluCide-I(TM) trials will take place in 'in vitro' cell culture using the Highly Pathogenic form of the H5N1 virus," said Dr. Diwan. "When data becomes available from the first part of these trials, NanoViricides, Inc. will process the data received, along with the data from the previously reported human influenza trials, and use it as the basis for our preliminary discussions with the FDA."
The Company also announced that it is actively seeking to build or acquire approximately 50,000 square feet of research and manufacturing space in the U.S. Once secured, the space will be modified to meet the FDA's GMP standards for drug manufacturing, pursuant to submitting INDAs to the FDA for FluCide-I and AviFluCide-I.
"Having a facility such as this is central to the NanoViricides, Inc. business plan," stated Dr. Eugene Seymour, CEO. "Not only will it provide additional space for expanded R&D, but it should eventually provide manufacturing capabilities for the drugs themselves."
About NanoViricides - nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricides, Inc., drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches.
. |
